Lecanemab in Early Alzheimer’s Disease
2022; Massachusetts Medical Society; Volume: 388; Issue: 1 Linguagem: Inglês
10.1056/nejmoa2212948
ISSN1533-4406
AutoresChristopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael C. Irizarry, Lynn D. Kramer, Takeshi Iwatsubo,
Tópico(s)Cholinesterase and Neurodegenerative Diseases
ResumoThe accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease.
Referência(s)